Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. Vienot A, et al. Among authors: bouattour m. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
[Corneal lesions during the treatment with amiodarone].
Bonamour G, Bonnet M, Bouattour M. Bonamour G, et al. Among authors: bouattour m. Bull Soc Ophtalmol Fr. 1970 Apr;70(4):534-8. Bull Soc Ophtalmol Fr. 1970. PMID: 5474592 French. No abstract available.
Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.
Gauci ML, Baroudjian B, Bédérède U, Zeboulon C, Delyon J, Allayous C, Madelaine I, Eftekhari P, Resche-Rigon M, Poté N, Paradis V, Durand F, Lebbé C, Roux O, Bouattour M; PATIO group. Gauci ML, et al. Among authors: bouattour m. Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101491. doi: 10.1016/j.clinre.2020.06.016. Epub 2020 Aug 6. Clin Res Hepatol Gastroenterol. 2021. PMID: 32773362
[Targeted therapies in hepatocellular carcinoma].
Bouattour M, Marijon H, Dreyer C, Faivre S, Raymond E. Bouattour M, et al. Presse Med. 2010 Jul-Aug;39(7-8):753-64. doi: 10.1016/j.lpm.2009.11.016. Epub 2010 Apr 7. Presse Med. 2010. PMID: 20378303 French.
Novel molecular therapies in hepatocellular carcinoma.
Faivre S, Bouattour M, Raymond E. Faivre S, et al. Among authors: bouattour m. Liver Int. 2011 Jan;31 Suppl 1:151-60. doi: 10.1111/j.1478-3231.2010.02395.x. Liver Int. 2011. PMID: 21205154 Review.
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E. Faivre S, et al. Among authors: bouattour m. Clin Cancer Res. 2011 Jul 1;17(13):4504-12. doi: 10.1158/1078-0432.CCR-10-1708. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531821 Clinical Trial.
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Ronot M, et al. Among authors: bouattour m. Oncologist. 2014 Apr;19(4):394-402. doi: 10.1634/theoncologist.2013-0114. Epub 2014 Mar 20. Oncologist. 2014. PMID: 24652387 Free PMC article.
89 results